Evidence map›Paper›PMID 24741628›Full record

ArticleJournal of immunology research2014

Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients.

Yazan S Khaled, Basil J Ammori, Eyad Elkord

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene.Frontiers in cell and developmental biology · 2022
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Yazan S KhaledInstitutes of Cancer, Inflammation & Repair, University of Manchester, Manchester M20 4BX, UK ; Biomedical Research Centre, School of Environment & Life Sciences, University of Salford, The Crescent, Peel Building, Manchester M5 4WT, UK ; Department of Upper Gastrointestinal Surgery, Salford Royal NHS Foundation Trust, Manchester M6 8HD, UK ; Department of Hepatobiliary Surgery, North Manchester General Hospital, Manchester M8 5RB, UK ; Section of Translational Anaesthetic and Surgical Sciences, Leeds Institute of Molecular Medicine, Leeds LS9 7TF, UK.
Basil J AmmoriInstitutes of Cancer, Inflammation & Repair, University of Manchester, Manchester M20 4BX, UK ; Biomedical Research Centre, School of Environment & Life Sciences, University of Salford, The Crescent, Peel Building, Manchester M5 4WT, UK ; Department of Upper Gastrointestinal Surgery, Salford Royal NHS Foundation Trust, Manchester M6 8HD, UK ; Department of Hepatobiliary Surgery, North Manchester General Hospital, Manchester M8 5RB, UK.
Eyad ElkordInstitutes of Cancer, Inflammation & Repair, University of Manchester, Manchester M20 4BX, UK ; Biomedical Research Centre, School of Environment & Life Sciences, University of Salford, The Crescent, Peel Building, Manchester M5 4WT, UK ; College of Medicine & Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, UAE.
University of Manchester · GBNorth Manchester General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) often presents late with poor survival. While role of immunosuppressive cells in preclinical studies provided help to develop immunotherapeutic agents, these cells remain under investigation in PC. The aim of this study was to characterise the different subsets of myeloid-derived suppressor cells (MDSCs) and evaluate their level and function in the circulation and tissue of PC patients. Significant increases in circulating and tumour-infiltrating granulocytic (Lin-HLA-DR-CD33+CD11b+CD15+), but not monocytic (Lin-HLA-DR-CD14+), MDSCs were detected in PC patients when compared with healthy donors and patients with chronic pancreatitis. The circulating MDSCs from PC patients expressed arginase 1, which represents their functional state. Blood levels of MDSCs showed no association with PC stage or preoperative levels of tumour markers. These findings provide a first characterisation of the phenotype of different subsets of peripheral and local MDSCs in PC patients and suggest that the frequency and contribution of these cells are predominantly granulocytic. This information demonstrates that MDSCs play a role in pancreatic cancer and future large validation studies may help in the development of new immunotherapeutic strategies to inhibit or eliminate MDSC function.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntigens, CDArginaseBiomarkers, TumorCase-Control StudiesFemaleGene ExpressionGranulocytesHLA-DR AntigensHumansImmunophenotypingLeukocyte CountMaleAntigens, CDARG1 protein, humanArginaseBiomarkers, TumorHLA-DR AntigensNeoplasm Proteins

Identifiers

PMID24741628
PMCPMC3987936
OpenAlexW2062721793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.